Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths

In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of...

Descripción completa

Detalles Bibliográficos
Autores principales: Strollo, Rocky, Maddaloni, Ernesto, Dauriz, Marco, Pedone, Claudio, Buzzetti, Raffaella, Pozzilli, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492144/
https://www.ncbi.nlm.nih.gov/pubmed/32946854
http://dx.doi.org/10.1016/j.diabres.2020.108444
Descripción
Sumario:In a nationwide study of 3818 charts from patients with fatal COVID-19, we found that geographical differences in Dipeptidyl peptidase 4 (DPP4) inhibitors use did not correlate with diabetes prevalence among COVID-19 deaths, thus not supporting the hypothesis of a clinically relevant involvement of DPP4 inhibition in COVID-19 development and progression.

Ejemplares similares